A novel misoprostol delivery system for induction of labor: clinical utility and patient considerations

Megan L Stephenson, Deborah A Wing, Megan L Stephenson, Deborah A Wing

Abstract

Induction of labor is one of the most commonly performed obstetric procedures and will likely become more common as the reproductive population in developed nations changes. As the proportion of women undergoing induction grows, there is a constant search for more efficacious ways to induce labor while maintaining fetal and maternal safety as well as patient satisfaction. With almost half of induced labors requiring cervical ripening, methods for achieving active labor and vaginal delivery are constantly being investigated. Prostaglandins have been shown to be effective induction agents, and specifically vaginal misoprostol, used off-label, have been widely utilized to initiate cervical ripening and active labor. The challenge is to administer this medication accurately while maintaining the ability to discontinue the medication when needed. The misoprostol vaginal insert initiates cervical ripening utilizing a delivery system that controls medication release and can be rapidly removed. This paper reviews the design, development, and clinical utility of the misoprostol vaginal insert for induction of labor as well as patient considerations related to the delivery system.

Keywords: cervical ripening; induction; misoprostol; vaginal insert.

Figures

Figure 1
Figure 1
Prostaglandin E1.

References

    1. Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2012. Natl Vital Stat Rep. 2013;62(3):1–20.
    1. National Institute for Health and Care Excellence Guideline CG70: Induction of labour. 2008. [Accessed November 18, 2014]. Available from: .
    1. Information Services Division, National Services Scotland Births in Scottish hospitals, year ending 31 March 2013. 2014. [Accessed November 17, 2014]. Available from:
    1. Maternity Statistics, Wales: Method of delivery, 2003–2013. 2014. [Accessed November 17, 2014]. Available from: .
    1. National Health Servise Maternity Statistics – England, 2012–2013. 2013. [Accessed November 17, 2014]. Available from: .
    1. Osmundson S, Ou-Yang RJ, Grobman WA. Elective induction compared with expectant management in nulliparous women with an unfavorable cervix. Obstet Gynecol. 2011;117(3):583–587.
    1. Cheng YW, Kaimal AJ, Snowden JM, Nicholson JM, Caughey AB. Induction of labor compared to expectant management in low-risk women and associated perinatal outcomes. Am J Obstet Gynecol. 2012;207(6):502.e501–e508.
    1. Darney BG, Snowden JM, Cheng YW, et al. Elective induction of labor at term compared with expectant management: maternal and neonatal outcomes. Obstet Gynecol. 2013;122(4):761–769.
    1. Sanchez-Ramos L, Olivier F, Delke I, Kaunitz AM. Labor induction versus expectant management for postterm pregnancies: a systematic review with meta-analysis. Obstet Gynecol. 2003;101(6):1312–1318.
    1. Stock SJ, Ferguson E, Duffy A, Ford I, Chalmers J, Norman JE. Outcomes of elective induction of labour compared with expectant management: population based study. BMJ. 2012;344:e2838.
    1. Caughey AB. Induction of labour: does it increase the risk of cesarean delivery? BJOG. 2014;121(6):658–661.
    1. Gulmezoglu AM, Crowther CA, Middleton P, Heatley E. Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev. 2012;6:CD004945.
    1. Bailit JL, Grobman W, Zhao Y, et al. Nonmedically indicated induction vs expectant treatment in term nulliparous women. Am J Obstet Gynecol. 2015;212(1):103.e1–e7.
    1. Spong CY. Defining “term” pregnancy: recommendations from the Defining “Term” Pregnancy Workgroup. JAMA. 2013;309(23):2445–2446.
    1. Spong CY, Berghella V, Wenstrom KD, Mercer BM, Saade GR. Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. Obstet Gynecol. 2012;120(5):1181–1193.
    1. Kolas T, Hofoss D, Daltveit AK, et al. Indications for cesarean deliveries in Norway. Am J Obstet Gynecol. 2003;188(4):864–870.
    1. Mealing NM, Roberts CL, Ford JB, Simpson JM, Morris JM. Trends in induction of labour, 1998–2007: a population-based study. Aust N Z J Obstet Gynaecol. 2009;49(6):599–605.
    1. Kelly AJ, Malik S, Smith L, Kavanagh J, Thomas J. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2009;4:CD003101.
    1. Bishop EH. Pelvic scoring for elective induction. Obstet Gynecol. 1964;24:266–268.
    1. Vrouenraets FP, Roumen FJ, Dehing CJ, van den Akker ES, Aarts MJ, Scheve EJ. Bishop score and risk of cesarean delivery after induction of labor in nulliparous women. Am J Obstet Gynecol. 2005;105(4):690–697.
    1. Laughon SK, Zhang J, Troendle J, Sun L, Reddy UM. Using a simplified Bishop score to predict vaginal delivery. Am J Obstet Gynecol. 2011;117(4):805–811.
    1. ACOG Committee on Practice Bulletins – Obstetrics ACOG Practice Bulletin No. 107: induction of labor. Am J Obstet Gynecol. 2009;114(2 Pt 1):386–397.
    1. Smith R. Parturition. N Engl J Med. 2007;356(3):271–283.
    1. Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2014;6:CD003101.
    1. Hofmeyr GJ, Gulmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2010;10:CD000941.
    1. Liu A, Lv J, Hu Y, Lang J, Ma L, Chen W. Efficacy and safety of intravaginal misoprostol versus intracervical dinoprostone for labor induction at term: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2014;40(4):897–906.
    1. Powers BL, Wing DA, Carr D, Ewert K, Di Spirito M. Pharmacokinetic profiles of controlled-release hydrogel polymer vaginal inserts containing misoprostol. J Clin Pharmacol. 2008;48(1):26–34.
    1. Rayburn WF, Powers BL, Plasse TF, Carr D, Di Spirito M. Pharmacokinetics of a controlled-release misoprostol vaginal insert at term. J Soc Gynecol Investig. 2006;13(2):112–117.
    1. US Food and Drug Administration Full revised misoprostol (Cytotec) label – Searle. 2002. [Accessed November 18, 2014]. Available from: .
    1. Castaneda CS, Izquierdo Puente JC, Leon Ochoa RA, Plasse TF, Powers BL, Rayburn WF. Misoprostol dose selection in a controlled-release vaginal insert for induction of labor in nulliparous women. Am J Obstet Gynecol. 2005;193(3 Pt 2):1071–1075.
    1. Frohn WE, Simmons S, Carlan SJ. Prostaglandin E2 gel versus misoprostol for cervical ripening in patients with premature rupture of membranes after 34 weeks. Obstet Gynecol. 2002;99(2):206–210.
    1. Wing DA, Powers BL, Rayburn WF. Determining dose and endpoints of a controlled-release misoprostol vaginal insert for a phase III trial. J Reprod Med. 2008;53(9):695–696.
    1. Ewert K, Powers B, Robertson S, Alfirevic Z. Controlled-release misoprostol vaginal insert in parous women for labor induction: a randomized controlled trial. Obstet Gynecol. 2006;108(5):1130–1137.
    1. Wing DA, Misoprostol Vaginal Insert Consortium Misoprostol vaginal insert compared with dinoprostone vaginal insert: a randomized controlled trial. Obstet Gynecol. 2008;112(4):801–812.
    1. Pevzner L, Alfirevic Z, Powers BL, Wing DA. Cardiotocographic abnormalities associated with misoprostol and dinoprostone cervical ripening and labor induction. Eur J Obstet Gynecol Reprod Biol. 2011;156(2):144–148.
    1. Wing DA, Miller H, Parker L, Powers BL, Rayburn WF, Misoprostol Vaginal Insert Miso-Obs-204 Investigators Misoprostol vaginal insert for successful labor induction: a randomized controlled trial. Obstet Gynecol. 2011;117(3):533–541.
    1. Stephenson ML, Powers BL, Wing DA. Fetal heart rate and cardiotocographic abnormalities with varying dose misoprostol vaginal inserts. J Matern Fetal Neonatal Med. 2013;26(2):127–131.
    1. Wing DA, Brown R, Plante LA, Miller H, Rugarn O, Powers BL. Misoprostol vaginal insert and time to vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2013;122(2 Pt 1):201–209.
    1. Gatward H, Simpson M, Woodhart L, Stainton MC. Women’s experiences of being induced for post-date pregnancy. Women Birth. 2010;23(1):3–9.
    1. Henderson J, Redshaw M. Women’s experience of induction of labor: a mixed methods study. Acta Obstet Gynecol Scand. 2013;92(10):1159–1167.
    1. Shetty A, Burt R, Rice P, Templeton A. Women’s perceptions, expectations and satisfaction with induced labour – a questionnaire-based study. Eur J Obstet Gynecol Reprod Biol. 2005;123(1):56–61.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren